Chinese inhibitor drug candidate becomes first to enter phase
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles
Student fatally shot, suspect detained at Georgia's Kennesaw State University
ATLANTA (AP) — Officials at Georgia’s Kennesaw State University say a student was killed in a weeken2024-05-21Leverkusen defender Jonathan Tah looks to finish historic season unbeaten and with more trophies
LEVERKUSEN, Germany (AP) — Jonathan Tah is already a German champion with Bayer Leverkusen. He’s hun2024-05-21- French President Macron laid on a crunching tackle as he took to the field for a charity football ma2024-05-21
Noah Cyrus flashes her bottom in extremely low
Noah Cyrus shared a slew of racy snaps to social media on Tuesday amid her ongoing family feud. The2024-05-21Trump accepts a VP debate but wants it on Fox News. Harris has already said yes to CBS
NEW YORK (AP) — Donald Trump said Friday his campaign has accepted an invitation from Fox News for h2024-05-21Third man is detained in a major bribery case that involves Russia's deputy defense minister
A third man has been detained in a bribery case involving a Russian deputy defense minister, Moscow’2024-05-21
atest comment